For research use only. Not for therapeutic Use.
Lemborexant (CAS 1369764-02-2) is a novel dual orexin receptor antagonist approved for the treatment of insomnia, addressing difficulties with sleep onset and maintenance. By selectively targeting orexin receptors, Lemborexant modulates the wake-sleep cycle, promoting natural and sustained sleep. Its distinct mechanism, which differs from traditional hypnotics, offers an alternative for individuals struggling with insomnia. Lemborexant’s approval underscores its potential as an effective therapeutic option for managing sleep-related issues, providing a new avenue for patients seeking relief from insomnia symptoms.
| Catalog Number | I048010 |
| CAS Number | 1369764-02-2 |
| Synonyms | Lemborexant; E-2006; |
| Molecular Formula | C22H20F2N4O2 |
| Purity | 98% |
| Target | OX1/2 inhibitor |
| Target Protein | MUGXRYIUWFITCP-PGRDOPGGSA-N |
| Appearance | Solid |
| IC50 | Ki= 0.61 nM for hOX2R Ki = 4.8 nM for hOX1R |
| IUPAC Name | (1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide |
| InChI | InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1 |
| InChIKey | MUGXRYIUWFITCP-PGRDOPGGSA-N |
| SMILES | CC1=NC(=NC=C1OCC2(CC2C(=O)NC3=NC=C(C=C3)F)C4=CC(=CC=C4)F)C |
